Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 14, Number 4—April 2008

Research

Seroprevalence and Risk Factors for Human Herpesvirus 8 Infection, Rural Egypt1

Sam M. Mbulaiteye*Comments to Author , Ruth M. Pfeiffer*, Bryan Dolan*, Victor C.W. Tsang†, John Noh†, Nabiel N.H. Mikhail‡, Mohamed Abdel-Hamid§¶, Mohamed Hashem§¶, Denise Whitby#, G. Thomas Strickland¶, and James J. Goedert*
Author affiliations: *National Cancer Institute, Bethesda, Maryland, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Assiut University, Cairo, Egypt; §National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; ¶University of Maryland School of Medicine, Baltimore, Maryland, USA; #National Cancer Institute-Frederick, Frederick, MD, USA;

Main Article

Table 3

Adjusted OR of association of HHV-8 seropositivity with demographic and clinical variables among adults, Egypt*

Characteristic Men
Women
OR 95% CI p value OR 95% CI p value
Age group, y† 0.002
15–24 Ref Ref
25–34 1.6 1.2–2.2 0.8 0.4–1.6 0.53
35–44 2.6 1.4–4.9 1.5 0.8–2.9 0.15
>45
4.3
1.7–11.0


3.1
1.5–6.4
<0.001
Dental treatments‡ 0.04
No Ref
Yes
2.3
1.1–4.9





HCV serostatus‡ 0.007
Negative Ref
Positive




3.3
1.4–7.9

Schistosomiasis§ 0.47 0.07
Negative Ref Ref
Positive 2.3 0.3–16.1 1.5 1.0–2.5

*OR, odds ratio; HHV-8, human herpesvirus 8; CI, confidence interval; Ref, referrent; HCV, hepatitis C virus.
†p value is for age group fitted with trend among men; p values for heterogeneity for categories given for women (see Statistical Methods).
‡Missing values in sex-specific analyses mean the variable was not significant and was excluded from final multivariable model.
§Schistosomiasis seropositivity was included in models even when not significant because we hypothesized a priori that it was associated with HHV-8 seropositivity (see online Appendix, available from www.cdc.gov/EID/content/14/4/586-app.htm).

Main Article

1Results were presented, in part, at the 9th International Workshop on Kaposi’s Sarcoma–associated Herpesvirus (KSHV) and Related Agents, Cape Cod, Massachusetts, USA, July 12–15, 2006.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO